- Home
- Automated
- List of product information
- CEFAZOLIN ALVOGEN POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL [SIN14846P]
CEFAZOLIN ALVOGEN POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL [SIN14846P]
Active ingredients: CEFAZOLIN ALVOGEN POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL
On this page
Product Info
CEFAZOLIN ALVOGEN POWDER FOR SOLUTION FOR INJECTION OR INFUSION 1G/VIAL
[SIN14846P]
Product information
Active Ingredient and Strength | CEFAZOLIN SODIUM 1.048 G EQV TO CEFAZOLIN - 1 G |
Dosage Form | INJECTION, POWDER, FOR SOLUTION |
Manufacturer and Country | SINOPHARM ZHIJUN (SHENZHEN) PHARMACEUTICAL CO., LTD - CHINA |
Registration Number | SIN14846P |
Licence Holder | NOVEM PHARMA PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J01DB04 |
4.1 Therapeutic indications
CEFAZOLIN ALVOGEN is indicated in adults and children for the treatment of the following infections due to bacteria which are susceptible to cefazolin:
Respiratory tract infections.
Sepsis.
Skin and soft tissue infections.
Endocarditis.
Urinary tract and genital infections.
Bile duct infections.
Bone and joint infections.
Other indications that require only intravenous administration:
CEFAZOLIN ALVOGEN is indicated for pre-operative prophylaxis of post-operative infections in:
Neurosurgery (craniotomy, liquor derivation).
Cardiac surgery.
Thoracic surgery.
Vascular surgery.
Gastro-intestinal surgery.
Hepatobiliary surgery.
Caesarean section.
Abdominal or vaginal hysterectomy.
Surgery of the head and neck with oropharynx opening.
Orthopaedic surgery.
Consideration should be given to official guidance on the appropriate use of antibiotics.
4.2 Posology and method of administration
Posology
Recommended dosage for intravenous administration
The following doses can be adjusted depending on the severity of the infection:

The safety of cefazolin in pre-term newborns and neonates has not been established. Therefore, the use of cefazolin is not recommended.
Recommended dosage for intramuscular administration
The following doses can be adjusted depending on the severity of the infection:

Recommended dosage in patients with renal impairment
Severe infections:

Mild infections:

Prophylaxis of post-operative infections
Generally, the prophylactic administration of the medicinal product should be short-term – within 24 to 48 hours.
The usual dose is 1 g intravenously administered during the induction of anaesthesia, followed by a dose of 0.5–1 g administered intravenously every 6–8 hours for 24 hours postoperatively.
For operative procedures lasting longer than 2 hours, 0.5–1 g is administered intravenously during surgery.
Method of administration
CEFAZOLIN ALVOGEN is administered by deep intramuscular injection or by intravenous bolus injection or infusion.
The powder for solution for injection or infusion should be initially diluted with 2–3 ml of diluent.
The solution should be further reconstituted as follows:
Intramuscular injection:
The solution is further reconstituted with water for injection (concentration of the solution 250 mg/ml).
Intravenous injection:
The solution is further reconstituted with water for injection (concentration of the solution 100 mg/ml).
CEFAZOLIN ALVOGEN may be administered either by slow intravenous injection over a period of 3 to 5 min directly into a vein or via a drip tube.
Intravenous infusion:
The solution is further reconstituted with one of the following compatible diluents (concentration of the solution 20 mg/ml):
0.9% NaCl Injection,
5% Glucose Injection,
10% Glucose Injection,
5% Glucose and 0.9% NaCl Injection,
5% Glucose and 0.45% NaCl Injection,
5% Glucose and 0.225% NaCl Injection,
4% Glucose and 0.18% NaCl Injection,
Compound sodium chloride injection,
Lactated Ringer’s injection.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
4.3 Contraindications
Hypersensitivity to the active substance or any other cephalosporins.
Pre-term newborns and neonates
The safety of cefazolin in pre-term newborns and neonates has not been established. Therefore, the use of cefazolin is not recommended.
